3-氯苄基脲 | 20940-42-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氯苄基脲
• 英文名称: 1-(3-chloro-phenyl)-3-methyl-urea
• 英文别名: N-(3-chloro-phenyl)-N'-methyl-urea；N-(3-Chlor-phenyl)-N'-methyl-harnstoff；N-Methyl-N'-(3-chlorophenyl)urea；N-<3-Chlor-phenyl>-N'-methyl-harnstoff；1-(3-Chlorophenyl)-3-methylurea
• CAS: 20940-42-5
• 化学式: C₈H₉ClN₂O
• mdl: MFCD00018402
• 分子量: 184.625
• InChiKey: MIRQKFUBAFNLEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  3-氯苄基脲 在 palladium on activated charcoal 盐酸 、 sodium hydroxide 、 氢气 、 乙酸酐 、 sodium nitrite 作用下， 以 甲醇 、 水 、 乙酸乙酯 为溶剂， 反应 13.0h， 生成 5,6-diamino-1-(3-chlorophenyl)-3-methyl-2,4 (1H, 3H)-pyrimidinedione
  参考文献：
  名称：

  Structure and activity relationships of novel uracil derivatives as topical anti-inflammatory agents

  摘要：

  In order to create novel, topical anti-inflammatory compounds exhibiting more potent activities than lead compound CX-659S (1), we designed and synthesized various derivatives of 1 focusing on the uracil N(l)- and N(3)-substituents, and evaluated their anti-inflammatory activities via inhibition of the picryl chloride-induced contact hypersensitivity reaction (CHR) in mice. In the course of our structure and activity relationship study, we found that compounds 6k, 6q, and 6r inhibited by approximately 50% the CHR, at 0.1 mg/ear. These activities were essentially equipotent with that of Tacrolimus, a strong immunosuppressant. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.09.012
• 作为产物：
  描述：

  异氰酸甲酯 、 3-氯苯胺 在 苯 作用下， 生成 3-氯苄基脲
  参考文献：
  名称：

  Boehmer, Recueil des Travaux Chimiques des Pays-Bas, 1936, vol. 55, p. 379,383

  摘要：

  DOI：

文献信息

• 1-arylpyrimidine derivatives and pharmaceutical use thereof
  申请人：Japan Energy Corporation

  公开号：US05661153A1

  公开（公告）日：1997-08-26

  The present invention relates to 1-arylpyrimidine derivatives represented by general formula (I): ##STR1## wherein R.sub.1 is H, alkyl or aralkyl; Ar is 1-naphthyl, or a substituted or unsubstituted phenyl group; R.sub.4 is a substituted phenyl, a substituted styryl, 1-methylcyclohexyl, 4-methylcyclohexyl, 4-oxo-4H-pyran-2-yl or 2-oxo-2H-pyran-5-yl group; R.sub.5 and R.sub.6 are each independently H or alkyl; R.sub.3 is H, and R.sub.7 and R.sub.8 are combined together to be oxo, or else R.sub.3 and R.sub.7 are combined together to be another direct bond, and R.sub.5 and R.sub.8 are combined together to be a direct bond, or pharmaceutically acceptable salts thereof; and methods for treating allergic diseases with such compounds.

  本发明涉及由通用公式(I)表示的1-芳基嘧啶衍生物：##STR1## 其中R.sub.1是H，烷基或芳烷基；Ar是1-萘基，或一个取代的或未取代的苯基；R.sub.4是一个取代的苯基，一个取代的苯乙烯基，1-甲基环己基，4-甲基环己基，4-氧代-4H-吡喃-2-基或2-氧代-2H-吡喃-5-基团；R.sub.5和R.sub.6各自独立是H或烷基；R.sub.3是H，R.sub.7和R.sub.8组合在一起形成氧代，或者R.sub.3和R.sub.7组合在一起形成另一个直接键，R.sub.5和R.sub.8组合在一起形成一个直接键，或其药用可接受盐；以及使用此类化合物治疗过敏性疾病的方法。
• Kinetics and Mechanism of Decompositions of<i>N</i>-Methyl-<i>N</i>′-aryl-<i>N</i>-nitrosoureas and Related Compounds in Aqueous Buffer Solution
  作者：Kitaro Yoshida、Kazuyuki Yano

  DOI：10.1246/bcsj.55.2200

  日期：1982.7

  The decomposition reactions of N-methyl-N′-aryl-N-nitrosoureas (1) and of N,N′-dimethyl-N′-aryl-N-nitrosoureas (2) were studied kinetically in phosphate buffer solution. All nitrosoureas 1 were easily hydrolyzed even under neutral conditions and the rates of hydrolysis were found to be proportional to the hydroxide ion concentration over pH range 5.4–7.6. General base catalysis by buffer components

  N-甲基-N'-芳基-N-亚硝基脲（1）和N，N'-二甲基-N'-芳基-N-亚硝基脲（2）在磷酸盐缓冲溶液中的分解反应动力学研究。即使在中性条件下，所有亚硝基脲 1 也很容易水解，并且发现水解速率与 pH 值范围 5.4-7.6 内的氢氧根离子浓度成正比。缓冲液成分的一般碱催化作用可以忽略不计。该反应经历消除机制，其中作为初始步骤涉及脲基质子的提取。另一方面，亚硝基脲 2 在相同条件下没有显着的反应性。
• Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
  申请人：Kshirsagar A. Tushar

  公开号：US20080015184A1

  公开（公告）日：2008-01-17

  Imidazopyridine, imidazoquinoline, and imidazonaphthyridine compounds having a urea substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

  本发明涉及在2-位具有脲基的咪唑吡啶，咪唑喹啉和咪唑萘啶化合物，含有这些化合物的药物组合物，中间体以及这些化合物的制备方法和使用方法，作为免疫调节剂，在动物中调节细胞因子生物合成，并用于治疗包括病毒和肿瘤疾病在内的疾病。
• 1-Arylpyrimidine derivatives and pharmaceutical use thereof
  申请人：JAPAN ENERGY CORPORATION

  公开号：EP0700908A1

  公开（公告）日：1996-03-13

  The present invention relates to pyrimidine derivatives of the formula (I): wherein    R₁ is H, alkyl or aralkyl;    Ar is 1-naphthyl, or a substituted or unsubstituted phenyl group;    R₄ is a substituted phenyl, a substituted styryl, 1-methylcyclohexyl, 4-methylcyclohexyl, 4-oxo-4H-pyran-2-yl or 2-oxo-2H-pyran-5-yl group;    R₅ and R₆ are each independently H or alkyl;    R₃ is H, and R₇ and R₈ are combined together to be oxo, or else R₃ and R₇ are combined together to be another direct bond, and R₅ and R₈ ar combined together to be a direct bond, or pharmaceutically acceptable salts thereof; and the use of such compounds in the treatment of an allergic disease.

  本发明涉及式（I）的嘧啶衍生物： 其中 R₁ 是 H、烷基或芳烷基； Ar 是 1-萘基或取代或未取代的苯基； R₄ 是取代的苯基、取代的苯乙烯基、1-甲基环己基、4-甲基环己基、4-氧代-4H-吡喃-2-基或 2-氧代-2H-吡喃-5-基； R₅ 和 R₆ 各自独立地为 H 或烷基； R₃为H，且R₇和R₈结合在一起为氧代，或者R₃和R₇结合在一起为另一个直接键，且R₅和R₈结合在一起为一个直接键，或其药学上可接受的盐；以及此类化合物在治疗过敏性疾病中的用途。
• Derivatives and methods of treating hepatitis B infections
  申请人：Novira Therapeutics, Inc.

  公开号：US10189835B2

  公开（公告）日：2019-01-29

  Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

  本文提供了用于治疗有需要的受试者 HBV 感染的化合物、其药物组合物以及抑制、抑制或预防受试者 HBV 感染的方法。